1. 339 Preliminary safety, tolerability and efficacy results of KN026 (a HER2-targeted Bispecific Antibody) in combination with KN046 (an anti-PD-L1/CTLA-4 Bispecific Antibody) in patients (pts) with HER2 aberrated solid tumors. (9th November 2020) Authors: Gong, Jifang; Dong, Zhi; Liu, Dan; Xu, June; Yang, Jing; Yang, Yue; Qi, Yakun; Men, Jie; Kong, Paul; Xu, Ting; Shen, Lin Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A207 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 810 Preliminary safety, tolerability and efficacy results of KN026 in combination with KN046 in patients with HER2 aberrated solid tumors. (10th December 2020) Authors: Gong, Jifang; Shen, Lin; Dong, Zhi; Liu, Dan; Xu, June; Yang, Jing; Yang, Yue; Qi, Yakun; Men, Jie; Kong, Paul; Xu, Ting Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A485 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 810 Preliminary safety, tolerability and efficacy results of KN026 in combination with KN046 in patients with HER2 aberrated solid tumors. (9th November 2020) Authors: Gong, Jifang; Shen, Lin; Dong, Zhi; Liu, Dan; Xu, June; Yang, Jing; Yang, Yue; Qi, Yakun; Men, Jie; Kong, Paul; Xu, Ting Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A861 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. A validated HPLC‐MS/MS method for determination of simmitecan and its metabolite chimmitecan in human plasma and its application to a pharmacokinetic study in Chinese patients with advanced solid tumor. Issue 21 (9th September 2021) Authors: Zhou, Jun; Zhan, Yan; Zhong, Dafang; Chen, Xiaoyan; Zhang, Yifan; Zhang, Qi; Bo, Yunhai; Shen, Lin; Gong, Jifang; Li, Jian; Yang, Fen Journal: Journal of separation science Issue: Volume 44:Issue 21(2021) Page Start: 3959 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Challenges in anticancer drug R&D in China. Issue 2 (February 2019) Authors: Zhao, Shen; Lv, Cheng; Gong, Jifang; Wenfeng, Fang; Hu, Xichun; Ba, Yi; Xiaoyuan, Chen; Zhimin, Yang; Shen, Lin; Zhang, Li Journal: Lancet oncology Issue: Volume 20:Issue 2(2019) Page Start: 183 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Clinical benefit of sunitinib in gastrointestinal stromal tumors with different exon 11 mutation genotypes. (October 2017) Authors: Dong, Zhi; Gao, Jing; Gong, Jifang; Li, Jie; Li, Yanyan; Shen, Lin; Li, Jian Journal: Future oncology Issue: Volume 13:Number 23(2017) Page Start: 2035 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Clinicopathologic features and treatment efficacy of Chinese patients with BRAF‐mutated metastatic colorectal cancer: a retrospective observational study. Issue 1 (16th October 2017) Authors: Wang, Xicheng; Wei, Qing; Gao, Jing; Li, Jian; Li, Jie; Gong, Jifang; Li, Yanyan; Shen, Lin Journal: Cancer communications Issue: Volume 36:Issue 1(2017) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer. Issue 6 (15th June 2022) Authors: Wang, Zhenghang; Zhang, Qi; Qi, Changsong; Bai, Yuezong; Zhao, Feilong; Chen, Hui; Li, Zhongwu; Wang, Xicheng; Chen, Mifen; Gong, Jifang; Peng, Zhi; Zhang, Xiaotian; Cai, Jinping; Chen, Shiqing; Zhao, Xiaochen; Shen, Lin; Li, Jian Journal: Journal for immunotherapy of cancer Issue: Volume 10:Issue 6(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma. (May 2021) Authors: Liu, Dan; Ma, Chunguang; Lu, Ping; Gong, Jifang; Ye, Dingwei; Wang, Siyang; Peng, Peijian; Bai, Yuxian; Song, Yuqin; Chen, Jianhua; Jiang, Ou; Zhang, Guojun; Ba, Yi; Chen, Li; Pan, Jianji; Li, Qi; Zhang, Liling; Gu, Shanzhi; Yin, Xianli; Cao, Bangwei Journal: European journal of cancer Issue: Volume 148(2021) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Dysregulated KRAS gene-signaling axis and abnormal chromatin remodeling drive therapeutic resistance in heterogeneous-sized circulating tumor cells in gastric cancer patients. (1st October 2021) Authors: Chen, Yang; Li, Yanyan; Qi, Changsong; Zhang, Cheng; Liu, Dan; Deng, Youping; Fu, Yuanyuan; Khadka, Vedbar S.; Wang, Daisy Dandan; Tan, Shanyang; Liu, Shujun; Peng, Zhi; Gong, Jifang; Lin, Peter Ping; Zhang, Xiaotian; Li, Jian; Li, Yilin; Shen, Lin Journal: Cancer letters Issue: Volume 517(2021) Page Start: 78 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗